---
title: Estimands and Analysis Considerations for Clinical Trials Impacted by COVID-19
author: ''
date: '2020-07-16T08:00:00-07:00'
slug: estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19
categories:
  - Clinical Trial
tags:
  - COVID-19
  - Estimand
  - DIA
type: webinar
url_register: ~
url_freeregister: ~
url_slides: ~
url_video: https://www.diaglobal.org/en/course-listing/webinar/on-demand/2020/07/dia-direct-estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19/presentation/16/estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19
url_agenda: ~
url_website: ~
url_audio: ~
url_code: ~
url_pdf: ~
date_end: '2020-07-16T09:30:00-07:00'
all_day: no
publishDate: '2021-03-23T10:34:14-07:00'
authors: []
featured: no
image:
  caption: ''
  focal_point: ''
  preview_only: no
slides: ''
projects: []
location: ~
address:
  street: ~
  city: ~
  region: ~
  postcode: ~
  country: ~
summary: ~
abstract: ~
speaker: Bohdana Ratitch (Bayer) | David J. Wright (AstraZeneca) | Xin Li (Genentech) | Daniel Meyer (Pfizer)  
---
<!--more-->
- The use of the estimand framework to assess and address pandemic-related disruptions  
- Analysis strategies for pandemic-related missing and unobservable values  

